AIM: To better predict treatment responses for managing bulky cervical carcinoma with neoadjuvant chemotherapy (NAC). METHODS: The expression of p-STAT3 was analyzed by immunohistochemistry using paraffin-embedded pretreatment cervical biopsy tissues. The study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with NAC. RESULTS: Twenty (69.0%) of 29 patients were scored as p-STAT3-positive. Pathological response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%). The p-STAT3-positive patients had a longer disease-free survival compared to p-STAT3-negative patients (P = 0.03), though they had more frequent clinical nodal involvement (P = 0.046). CONCLUSION: Pretreatment assessment of p-STAT3 expression may provide additional information for the identification of patients with cervical cancer who have a favorable prognosis.
AIM: To better predict treatment responses for managing bulky cervical carcinoma with neoadjuvant chemotherapy (NAC). METHODS: The expression of p-STAT3 was analyzed by immunohistochemistry using paraffin-embedded pretreatment cervical biopsy tissues. The study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with NAC. RESULTS: Twenty (69.0%) of 29 patients were scored as p-STAT3-positive. Pathological response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%). The p-STAT3-positive patients had a longer disease-free survival compared to p-STAT3-negative patients (P = 0.03), though they had more frequent clinical nodal involvement (P = 0.046). CONCLUSION: Pretreatment assessment of p-STAT3 expression may provide additional information for the identification of patients with cervical cancer who have a favorable prognosis.
Authors: W Huang; Z Dong; Y Chen; F Wang; C J Wang; H Peng; Y He; G Hangoc; K Pollok; G Sandusky; X-Y Fu; H E Broxmeyer; Z-Y Zhang; J-Y Liu; J-T Zhang Journal: Oncogene Date: 2015-06-15 Impact factor: 9.867